The Career Contessa website recently launched The Salary Project, a database to compare salaries within your industry and receive a personalized salary review service. Lauren McGoodwin, Founder and CEO of Career Contessa joins Your Cheddar to discuss why she feels salary transparency would create an equal work environment. McGoodwin believes salary transparency can create more of an open dialogue when it comes to closing the gender pay gap. Also, seeing what managers or superiors make could encourage employees to work harder to move up the food chain. Plus, how can you negotiate a salary you believe your skills deserve? McGoodwin says to make sure you know the difference between your self-worth and your net-worth. You can't make it personal when you don't get a raise. Your employer is paying you based on the skills you have, not the person you are.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More